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ested in a speciﬁc disease and through NDC codes when
interested in the medication. However, this methodology
may be different for a population of pain patients, as 
no ICD code speciﬁc for pain exists. The purpose of this
study was to understand the differences in data pulled
using NDC versus ICD-9 codes to identify a pain popu-
lation. METHODS: United Healthcare pharmacy and
medical claims from continuously enrolled individuals in
1998 were used for examination. In one method patients
were selected if they were at least 18 years of age as of
January 1, 1998, were continuously enrolled with a drug
and medical beneﬁt and had at least one medical claim
with a pain-related diagnosis (cancer, ﬁbromyalgia, low
back pain, neuropathic pain, and osteoarthritis) in 1998.
The other method differed by selecting patients who had
at least one pharmacy claim with an NDC for pain med-
ication (long acting opioid, short acting opioid, combi-
nation opioid and NSAID). RESULTS: Using the ICD
code method, 233,390 patients were selected. Low back
pain had the highest amount of people, constituting 40%,
while neuropathic pain had the least, 5%. The average
age of patients with pain-related diagnosis was 46.6.
Using the pharmacy claims method, 274,830 were
selected. The most commonly prescribed pain medication
was combination opioids (36%), and the least was long
acting opioids (0.7%). The mean age for this population
was 43.2. The overlap in patient selection was 84.9%
with the prescription drug population being a larger
cohort. CONCLUSIONS: Using NDC codes to select
users of pain medications in a database revealed more
users than those selected through ICD codes speciﬁc for
conditions where pain exists. However, an 85% overlap
in patient selection suggests that the diseases selected
capture a majority of pain-related conditions.
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OBJECTIVES: To deﬁne factors inﬂuencing the uptake
and use of newer, disease-altering agents such as
Betaseron, Avonex, Rebif and Copaxone in treatment of
multiple sclerosis (MS). METHODS: The analytic ﬁle for
the study was derived from claims and eligibility data for
a privately insured population for 1996–2000. Patients
were followed for a minimum of one year, starting with
their ﬁrst conﬁrmed diagnosis of MS. Disease Staging
software was used to establish disease type (e.g., relaps-
ing/remitting) during the study period. Disease type, cor-
morbidities, demographics, and insurance information
were measured to assess their importance on the odds of
receiving a disease-altering agent. A Cox proportional
hazard analysis was used to estimate the effect of each
variable. RESULTS: Forty-one percent of the 1807 MS
patients eventually were ever treated with the newer
disease-altering drugs. Of note is the elapsed time of
average of 305.2 days between the conﬁrmed ﬁrst-
observed MS diagnosis and ﬁrst prescription for one of
the newer agents. The hazard analyses found that older
patients, early retirees, and patients with union afﬁlia-
tion received the newer drugs less often. Gender, type of
private insurance, and location (urban versus rural) did
not inﬂuence the odds of getting the drugs. Patients resid-
ing in the Southern and Western United States, those that
entered the study in later years (1997–1999), and patients
with lower medication co-payments received the medica-
tions more often. Patients with a history of either depres-
sion or heart disease (relative contra-indications to these
drugs) received them less often. The variables designed to
measure disease severity suggested that stable patients,
those neither too sick nor healthy, received the drugs
more often. CONCLUSIONS: The use disease modifying
drugs for the treatment of MS introduced in the 1990s is
observed in a lower percentage of patients, and with a
greater delay from the date of conﬁrmed diagnosis than
anticipated given clinical literature for these newer agents.
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OBJECTIVES: To describe Three-Times daily (TID)
methylphenidate (MPH) therapy in children with atten-
tion-deﬁcit/hyperactivity disorder (ADHD) and to
measure the extent of compliance with TID MPH
therapy. METHODS: Parents of children aged 6–12 years
with ADHD receiving either MPH or dextroamphetamine
were invited to participate in a survey via newspaper ads
placed in 2 major Canadian cities (Toronto and Mon-
treal). Eligibility criteria were: treatment with TID MPH
and treatment duration of at least one month. Purposes
of the study and eligibility criteria were not known to
callers. RESULTS: One hundred seventy seven callers
responded to the ads. Of these, 60 (34%) fulﬁlled eligi-
bility criteria. The mean age of children with ADHD was
8.8 years; 78% were boys. Mean daily dose was 34mg;
mean treatment duration was 28.6 months. Twenty
percent had taken a drug holiday in the past 2 weeks
(mean 1.8 days). Doses were taken at approximately 7:30
AM, noon, and 4PM. A parent was primarily responsi-
ble for administering the 1st and 3rd doses. School per-
sonnel or teachers tended to administer the 2nd dose.
Seventy three percent reported their child missed doses
from time to time. Fifty three percent reported missing
doses, excluding drug holidays, in the past 2 weeks (mean
